Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.32 which represents a decrease of $-1.45 or -2.60% from the prior close of $55.77. The stock opened at $55.88 and ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

Bristol Myers Squibb reported strong third-quarter financial results, notching an 18% jump in its growth portfolio.

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Delving into the details, we found 8% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we ...

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics ...